Search - tctmd.com

Displaying 1 - 20 of 86

Sort: Relevancy | Date

News Conference News ESC 2025

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Caitlin E. Cox

September 01, 2025

News Conference News ACC 2025

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

Caitlin E. Cox

March 29, 2025

News Opinion Editor's Corner ACC 2025

What’s Going to Be Hot at ACC 2025?

Michael O'Riordan

March 26, 2025

News Daily News

Top Endovascular News of 2024

L.A. McKeown

December 28, 2024

News Conference News VIVA 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

L.A. McKeown

November 11, 2024

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

L.A. McKeown

November 06, 2024

News Daily News

Different Guidelines for Acute PE Offer a Mixed Bag of Advice

Caitlin E. Cox

October 08, 2024

News Daily News

Scientific Statement Reviews Current Antithrombotic Options in PAD

L.A. McKeown

August 26, 2024

News Daily News

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

L.A. McKeown

August 19, 2024

News Daily News

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Yael L. Maxwell

June 26, 2024

News Conference News ISET 2024

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

Caitlin E. Cox

January 31, 2024

News Conference News ISET 2024

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

Caitlin E. Cox

January 30, 2024

News Conference News ISET 2024

Venous Stents: How to Choose Among the Wealth of Options

Caitlin E. Cox

January 26, 2024

News Daily News

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

Shelley Wood

January 17, 2024

News Conference News VIVA 2023

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

L.A. McKeown

November 01, 2023

News Opinion CV Team Dispatch

October 2023 News Roundup

L.A. McKeown

October 01, 2023

News Daily News

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

L.A. McKeown

September 12, 2023

News Conference News ESC 2023

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

L.A. McKeown

August 30, 2023

News Conference News SCAI 2023

FLASH: PE Patients Show Ongoing Clinical, QoL Gains With Thrombectomy

L.A. McKeown

May 21, 2023

News Daily News

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

L.A. McKeown

March 29, 2023

Advertisement

HI-PRO: Oral Apixaban for 1 Year Protective, Safe in Provoked VTE Patients

Low-Dose Apixaban Prevents Recurrent VTE in Cancer Beyond 6 Months: API-CAT

What’s Going to Be Hot at ACC 2025?

Top Endovascular News of 2024

DETOUR 2: Endovascular Procedure That Mimics Femoral Bypass Durable at 3 Years

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

Different Guidelines for Acute PE Offer a Mixed Bag of Advice

Scientific Statement Reviews Current Antithrombotic Options in PAD

New Data Reassure on Rivaroxaban’s Role in Frail PAD Patients

Burden of CVD Still High in UK Despite Prevention Efforts Over 20 Years

Will IVUS Ever Take Off in Peripheral Vascular Interventions?

AI in Pulmonary Embolism: ‘Transformative’ for Patient Care

Venous Stents: How to Choose Among the Wealth of Options

DOAC Don’ts: New Review Clarifies When Not to Use Direct Oral Anticoagulants

PROMISE II: Deep-Vein Arterialization Durable for Amputation-Free Survival in CLTI

October 2023 News Roundup

FDA Approves Blood Flow-Diverting LimFlow System for No-Option CLTI

ONCO DVT Supports 12 Months of Preventive DOACs in Cancer Patients

FLASH: PE Patients Show Ongoing Clinical, QoL Gains With Thrombectomy

PROMISE II: Flow-Diverting Procedure May Save Limbs in CLTI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content